Figure 5.
Effect of AHR ligands on miR-29b expression in NK cells. (A-B) CD56+/Lineage negative NK cells were treated with DMSO (vehicle control) or FICZ (AHR agonist), or conditioned media obtained from U937 AML cells for 4 hours, and miR-29b expression was evaluated by RT-PCR. (C) Primary NK cells were cultured alone or in transwell with AML blasts either untreated or treated with CH223191. miR-29b expression was evaluated by qPCR, representative donor depicted, n = 3. (D) NK cells were treated with DMSO (vehicle control), AHR agonist (FICZ), or AHR antagonist (CH223191) for 48 hours, stimulated with IL-12 and IL-18, and evaluated for the production of soluble IFN-γ by enzyme-linked immunosorbent assay (Student t test, *P > .05). Error bars indicate SD.

Effect of AHR ligands on miR-29b expression in NK cells. (A-B) CD56+/Lineage negative NK cells were treated with DMSO (vehicle control) or FICZ (AHR agonist), or conditioned media obtained from U937 AML cells for 4 hours, and miR-29b expression was evaluated by RT-PCR. (C) Primary NK cells were cultured alone or in transwell with AML blasts either untreated or treated with CH223191. miR-29b expression was evaluated by qPCR, representative donor depicted, n = 3. (D) NK cells were treated with DMSO (vehicle control), AHR agonist (FICZ), or AHR antagonist (CH223191) for 48 hours, stimulated with IL-12 and IL-18, and evaluated for the production of soluble IFN-γ by enzyme-linked immunosorbent assay (Student t test, *P > .05). Error bars indicate SD.

Close Modal

or Create an Account

Close Modal
Close Modal